| Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial A Drilon, N Rekhtman, M Arcila, L Wang, A Ni, M Albano, ... The Lancet Oncology 17 (12), 1653-1660, 2016 | 409 | 2016 |
| SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization MK Baine, MS Hsieh, WV Lai, JV Egger, AA Jungbluth, Y Daneshbod, ... Journal of Thoracic Oncology 15 (12), 1823-1835, 2020 | 262 | 2020 |
| PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers JK Sabari, GC Leonardi, CA Shu, R Umeton, J Montecalvo, A Ni, R Chen, ... Annals of Oncology 29 (10), 2085-2091, 2018 | 262 | 2018 |
| SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas N Rekhtman, J Montecalvo, JC Chang, D Alex, RN Ptashkin, N Ai, ... Journal of Thoracic Oncology 15 (2), 231-247, 2020 | 208 | 2020 |
| Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score–matched analysis T Eguchi, K Kameda, S Lu, MJ Bott, KS Tan, J Montecalvo, JC Chang, ... Journal of thoracic oncology 14 (1), 87-98, 2019 | 180 | 2019 |
| Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers A Drilon, R Somwar, BP Mangatt, H Edgren, P Desmeules, A Ruusulehto, ... Cancer discovery 8 (6), 686-695, 2018 | 168 | 2018 |
| The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer AJ Schoenfeld, C Bandlamudi, JA Lavery, J Montecalvo, A Namakydoust, ... Clinical Cancer Research 26 (21), 5701-5708, 2020 | 156 | 2020 |
| Immunophenotype and response to immunotherapy of RET-rearranged lung cancers M Offin, R Guo, SL Wu, J Sabari, JD Land, A Ni, J Montecalvo, ... JCO precision oncology 3, 2019 | 122 | 2019 |
| Bronchiolar adenoma: expansion of the concept of ciliated muconodular papillary tumors with proposal for revised terminology based on morphologic, immunophenotypic, and genomic … JC Chang, J Montecalvo, L Borsu, S Lu, BT Larsen, WD Wallace, ... The American journal of surgical pathology 42 (8), 1010-1026, 2018 | 106 | 2018 |
| Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices N Rekhtman, P Desmeules, AM Litvak, MC Pietanza, ML Santos-Zabala, ... Modern pathology 32 (8), 1106-1122, 2019 | 67 | 2019 |
| Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations N Rekhtman, CM Pietanza, J Sabari, J Montecalvo, H Wang, O Habeeb, ... Modern Pathology 31 (1), 111-121, 2018 | 59 | 2018 |
| Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes JC Chang, M Offin, C Falcon, D Brown, BR Houck-Loomis, F Meng, ... Clinical Cancer Research 27 (14), 4066-4076, 2021 | 51 | 2021 |
| Histologic subtype in core lung biopsies of early-stage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation … JE Leeman, A Rimner, J Montecalvo, M Hsu, Z Zhang, D von Reibnitz, ... International Journal of Radiation Oncology* Biology* Physics 97 (1), 138-145, 2017 | 51 | 2017 |
| PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC). JK Sabari, J Montecalvo, R Chen, JA Dienstag, C Mrad, I Bergagnini, ... Journal of Clinical Oncology 35 (15_suppl), 8512-8512, 2017 | 47 | 2017 |
| Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: a propensity-matched analysis WS Brandt, W Yan, J Zhou, KS Tan, J Montecalvo, BJ Park, PS Adusumilli, ... The Journal of thoracic and cardiovascular surgery 157 (2), 743-753. e3, 2019 | 36 | 2019 |
| What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? EA Aherne, AJ Plodkowski, J Montecalvo, S Hayan, J Zheng, M Capanu, ... Lung Cancer 118, 83-89, 2018 | 33 | 2018 |
| Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers A Drilon, AJ Schoenfeld, KC Arbour, A Litvak, A Ni, J Montecalvo, ... Molecular Case Studies 5 (2), a003665, 2019 | 24 | 2019 |
| BRMS1 expression in surgically resected lung adenocarcinoma predicts future metastases and is associated with a poor prognosis PR Bucciarelli, KS Tan, NP Chudgar, W Brandt, J Montecalvo, T Eguchi, ... Journal of Thoracic Oncology 13 (1), 73-84, 2018 | 23 | 2018 |
| RET-rearranged lung cancers: Immunophenotype and response to immunotherapy. JK Sabari, MD Offin, SL Wu, A Ni, D Halpenny, J Montecalvo, D Liu, ... Journal of Clinical Oncology 36 (15_suppl), 9034-9034, 2018 | 18 | 2018 |
| MA12. 05 Can tumor spread through air spaces (STAS) in lung adenocarcinomas be predicted pre-and intraoperatively? K Kameda, S Lu, T Eguchi, N Rekhtman, J Chang, J Montecalvo, D Jones, ... Journal of Thoracic Oncology 12 (1), S411-S412, 2017 | 17 | 2017 |
